Physician
Presbyterian Healthcare Services
Presbyterian Healthcare Services was paid $33.04M by Medicaid between Jan 2018 and Dec 2024, across 207 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoPRESBYTERIAN HEALTHCARE SERVICES
RUIDOSO, NM 88345
RUIDOSO, NM 88345
33aNPI1558347708assigned 12/20/2005
33bProvider typeEmergency Medicine Physician
28Total paid$33.04M
24GClaims379,445
24DCodes billed207
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in New Mexico
Rank by total paid#6 of 39
Median peer was paid$669K
This provider vs. median49×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,852 | $4.07M | |
| 2019 | 49,936 | $3.82M | |
| 2020 | 32,225 | $2.94M | |
| 2021 | 45,705 | $3.77M | |
| 2022 | 63,063 | $5.39M | |
| 2023 | 80,073 | $7.68M | |
| 2024incomplete | 50,591 | $5.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 30,348 | 28,007 | $5.76M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 26,850 | 25,420 | $5.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 13,645 | 12,516 | $4.42M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.0% | 6,458 | 6,213 | $1.33M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 3.3% | 3,642 | 3,235 | $1.09M |
| A0425 | Ground mileage, per statute mile | 3.2% | 4,915 | 4,142 | $1.06M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 1,696 | 1,626 | $1.04M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 10,367 | 8,376 | $774K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 5,960 | 5,210 | $647K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 7,916 | 2,253 | $630K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 1,853 | 1,782 | $561K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 2,307 | 2,210 | $510K |
195 more codes
| A0429 | Emergency ambulance ride, basic life support | 1.5% | 1,802 | $505K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 3,287 | $451K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,288 | $407K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 5,749 | $394K |
| 80053 | Comprehensive metabolic panel | 1.1% | 21,339 | $347K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,045 | $324K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,520 | $316K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,560 | $282K |
| 87631 | <1% | 1,497 | $271K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,553 | $261K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,009 | $251K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,339 | $234K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,445 | $221K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,977 | $214K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 901 | $199K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 466 | $193K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,004 | $182K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,279 | $181K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,558 | $174K |
| 73562 | <1% | 1,060 | $170K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,900 | $140K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,899 | $140K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,161 | $123K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,825 | $121K |
| 59025 | Fetal non-stress test | <1% | 552 | $113K |
| 73610 | <1% | 690 | $112K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,533 | $111K |
| 73030 | <1% | 662 | $99K | |
| 81513 | <1% | 512 | $98K | |
| 84484 | <1% | 3,530 | $96K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,215 | $84K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 142 | $80K |
| 80306 | <1% | 2,267 | $75K | |
| G0378 | Hospital observation service, per hour | <1% | 119 | $74K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,254 | $71K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 393 | $66K |
| 73130 | <1% | 602 | $64K | |
| 73630 | <1% | 575 | $63K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,584 | $61K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,989 | $60K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,286 | $60K |
| 76830 | Ultrasound, transvaginal | <1% | 369 | $59K |
| 81001 | <1% | 7,666 | $55K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,558 | $55K |
| 81025 | <1% | 3,946 | $55K | |
| 83690 | <1% | 4,583 | $53K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 310 | $52K |
| 84439 | <1% | 4,316 | $52K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 344 | $51K |
| 87081 | <1% | 3,375 | $46K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,336 | $44K |
| 86803 | <1% | 2,247 | $43K | |
| 93976 | <1% | 192 | $43K | |
| 72100 | <1% | 241 | $42K | |
| 86780 | <1% | 2,082 | $38K | |
| 73110 | <1% | 356 | $38K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 115 | $38K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,005 | $37K |
| 83605 | <1% | 2,024 | $35K | |
| J3490 | Unclassified drugs | <1% | 8,699 | $35K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 314 | $35K |
| 81003 | <1% | 6,456 | $34K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 949 | $34K |
| A0998 | Ambulance response and treatment, no transport | <1% | 451 | $32K |
| 87077 | <1% | 2,177 | $31K | |
| 80061 | Lipid panel | <1% | 1,829 | $30K |
| 82077 | <1% | 1,690 | $30K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 51 | $30K |
| 83735 | <1% | 2,458 | $29K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,973 | $27K |
| 81514 | <1% | 80 | $27K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 698 | $26K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 446 | $26K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 171 | $25K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 525 | $25K |
| 85027 | <1% | 2,503 | $24K | |
| 87481 | <1% | 553 | $24K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,686 | $23K |
| 87040 | <1% | 849 | $23K | |
| 96376 | <1% | 521 | $23K | |
| 72110 | <1% | 154 | $22K | |
| 87186 | <1% | 1,460 | $21K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 320 | $18K |
| 85379 | <1% | 824 | $18K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 27 | $17K |
| 86850 | <1% | 1,014 | $16K | |
| 36000 | <1% | 782 | $16K | |
| 74018 | <1% | 134 | $16K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,049 | $16K |
| 87650 | <1% | 461 | $15K | |
| 85610 | <1% | 2,211 | $14K | |
| 93041 | <1% | 215 | $14K | |
| 86696 | <1% | 530 | $14K | |
| 82962 | <1% | 2,052 | $14K | |
| 83880 | <1% | 359 | $13K | |
| 97161 | <1% | 241 | $13K | |
| 90715 | <1% | 482 | $13K | |
| 84702 | <1% | 450 | $12K | |
| 86900 | <1% | 1,149 | $10K | |
| 87430 | <1% | 479 | $10K | |
| 80143 | <1% | 438 | $10K | |
| 81002 | <1% | 2,779 | $10K | |
| 80179 | <1% | 436 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 16 | $9K |
| 86695 | <1% | 529 | $9K | |
| 86787 | <1% | 508 | $9K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,080 | $9K |
| 86762 | <1% | 402 | $8K | |
| 0225U | <1% | 13 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,416 | $8K |
| 84153 | <1% | 318 | $8K | |
| 87340 | <1% | 520 | $8K | |
| 87653 | <1% | 141 | $7K | |
| 86901 | <1% | 1,150 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 125 | $7K |
| 86140 | <1% | 979 | $7K | |
| 83655 | <1% | 355 | $6K | |
| 29125 | <1% | 24 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 553 | $6K |
| 87660 | <1% | 196 | $5K | |
| 87510 | <1% | 191 | $5K | |
| 87480 | <1% | 193 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 95 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,282 | $4K |
| 82728 | <1% | 226 | $4K | |
| 97162 | <1% | 85 | $4K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 17 | $4K |
| 73080 | <1% | 28 | $4K | |
| 70486 | <1% | 13 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 624 | $4K |
| 82570 | <1% | 597 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $4K |
| 82607 | <1% | 185 | $4K | |
| 85652 | <1% | 486 | $4K | |
| 80050 | General health panel | <1% | 261 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 205 | $4K |
| 93226 | <1% | 16 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,295 | $3K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 70 | $3K |
| 73502 | <1% | 27 | $3K | |
| 82043 | <1% | 398 | $3K | |
| 85014 | <1% | 719 | $3K | |
| 90670 | <1% | 212 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 686 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 14 | $2K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 25 | $2K |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 54 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 41 | $2K |
| 85018 | <1% | 567 | $2K | |
| 97750 | <1% | 52 | $2K | |
| 80076 | <1% | 142 | $2K | |
| 82950 | <1% | 247 | $2K | |
| 97602 | <1% | 34 | $2K | |
| 83540 | <1% | 172 | $2K | |
| 82550 | <1% | 154 | $1K | |
| 83550 | <1% | 126 | $1K | |
| 76857 | <1% | 12 | $1K | |
| 90461 | <1% | 25 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 469 | $1K |
| 86694 | <1% | 56 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 581 | $996.72 |
| 73090 | <1% | 16 | $949.40 | |
| 85730 | <1% | 102 | $881.07 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 33 | $824.38 |
| 84403 | <1% | 27 | $818.78 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $793.76 |
| 84100 | <1% | 86 | $792.08 | |
| 80074 | <1% | 12 | $783.67 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 341 | $777.62 |
| 87807 | <1% | 37 | $759.83 | |
| 94760 | <1% | 70 | $738.12 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 202 | $622.95 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 34 | $607.78 |
| 82274 | <1% | 26 | $518.93 | |
| 82670 | <1% | 12 | $515.01 | |
| 87070 | <1% | 42 | $452.19 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 224 | $443.57 |
| 90656 | <1% | 24 | $252.30 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 32 | $248.45 |
| 82272 | <1% | 54 | $248.19 | |
| 86038 | <1% | 12 | $246.97 | |
| 82140 | <1% | 14 | $238.78 | |
| 87205 | <1% | 43 | $235.28 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 28 | $231.03 |
| 82150 | <1% | 22 | $228.91 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 118 | $227.72 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 16 | $168.18 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 55 | $125.12 |
| S0028 | Injection, famotidine, 20 mg | <1% | 44 | $83.16 |
| G0008 | Administration of influenza virus vaccine | <1% | 51 | $63.87 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 14 | $47.02 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 13 | $43.00 |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 51 | $36.17 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15 | $30.28 |
| 90686 | <1% | 16 | $12.11 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBEAMES, BO (VP REGIONAL OPERATIONS)
| Provider | Location | Paid |
|---|---|---|
| Presbyterian Healthcare Services | Clovis, NM | $47.63M |
| Presbyterian Healthcare Services | Clovis, NM | $407K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.